Related Experiment Video
Updated: Jan 29, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of
Alice C O'Farrell1, Ian S Miller1, Rhys Evans1
1RCSI Centre for Systems Medicine, Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin 2, D02 HX03, Ireland.
Purpose:
The tyrosine kinase inhibitor (TKI) sunitinib is a multi-targeted agent approved across multiple cancer indications. Nevertheless, since approval, data has emerged to describe a worrisome side effect profile including hypertension, hand-foot syndrome, fatigue, diarrhea, mucositis, proteinuria, and (rarely) congestive heart failure. It has been hypothesized that the observed multi-parameter toxicity profile is related to "on-target" kinase inhibition in "off-target" tissues.
Experimental Design:
To interrogate off-target effects in pre-clinical studies, a reverse phase protein array (RPPA) approach is employed. Mice are treated with sunitinib (40 mg kg-1 ) for 4 weeks, following which critical organs are removed. The Zeptosens RPPA platform is employed for protein expression analysis.
Results:
Differentially expressed proteins associated with damage and/or stress are found in the majority of organs from treated animals. Proteins differentially expressed in the heart are associated with myocardial hypertrophy, ischaemia/reperfusion, and hypoxia. However, hypertrophy is not evidenced on histology. Mild proteinuria is observed; however, no changes in renal glomerular structure are visible via electron microscopy. In skin, proteins associated with cutaneous inflammation, keratinocyte hyper-proliferation, and increased inflammatory response are differentially expressed.
Conclusions And Clinical Relevance:
It is posited that pre-clinical implementation of a combined histopathological/RPPA approach provides a sensitive method to mechanistically elucidate the early manifestation of TKI on-target/organ off-target toxicities.
Insights
Sunitinib, a cancer drug, causes side effects by inhibiting kinases in non-cancerous tissues. This study used protein arrays to identify early molecular signs of sunitinib toxicity in mouse organs.
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Background:
- Sunitinib is a multi-targeted tyrosine kinase inhibitor (TKI) used in cancer treatment.
- TKIs can cause significant side effects, potentially due to inhibiting kinases in healthy tissues.
- Understanding these off-target effects is crucial for patient safety.
Purpose of the Study:
- To investigate the molecular mechanisms of sunitinib's off-target toxicities.
- To identify early molecular indicators of sunitinib-induced organ damage in pre-clinical models.
Main Methods:
- Mice were treated with sunitinib (40 mg/kg) for 4 weeks.
- Reverse Phase Protein Array (RPPA) was used for protein expression analysis in various organs.
- Histopathological examination was performed for correlation.
Main Results:
- Differentially expressed proteins related to stress and damage were found in most organs.
- Heart tissue showed proteins linked to myocardial hypertrophy, ischemia/reperfusion, and hypoxia, though histology was normal.
- Skin tissue exhibited proteins associated with inflammation and keratinocyte hyper-proliferation.
Conclusions:
- A combined RPPA and histopathology approach can detect early signs of TKI toxicity.
- This method helps elucidate the mechanisms of on-target/off-target toxicities.
- Early detection of molecular changes can inform strategies to mitigate TKI side effects.
Related Concept Videos
pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
Nursing Implementation
The five steps to implementing effective nursing care include reassessing the patient, reviewing and revising the existing nursing care plan, organizing the resources and care delivery, anticipating and preventing complications, and implementing nursing interventions.
Phase Transitions: Sublimation and Deposition
Phase Diagrams
Pre-mRNA Processing: Modification of pre-mRNA Ends
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a cap to the 5' end of the growing transcript. In this process, a 5' phosphate is replaced by modified guanosine that has a methyl group attached (7-methyl guanosine). This 5' cap helps...
Phase Transitions

